| Effect | None |
| Values | (× 10⁹ /L) Mean and SD. Placebo: before 6.2 ± 1.3, after 5.9 ± 1.3. Carnitine: before 6.7 ± 1.7, after 6.7 ± 1.6. |
| Trial Design | Randomized trial |
| Trial Length | 1-6 months |
| Number of Subjects | 52 |
| Sex | Both Genders |
In a randomized, double-blind, placebo-controlled trial, 52 participants with impaired glucose tolerance and fatty liver took 900 mg of l-carnitine in combination with metformin or placebo in combination with metformin daily for 12 weeks.
ALT was the primary outcome, and there was a statistically significantly greater reduction in the carnitine group, but not for AST or ALP. The reduction in hs-CRP and 8-OHdG were also statistically significant, though lipid profile, metabolic markers, blood pressure, and everything else wasn't.
